Video

Dr. Ghia on the Clinical Implications of the CAPTIVATE Trial in CLL

Author(s):

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Paolo Ghia, MD, PhD, full professor, Medical Oncology, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses the clinical implications of the phase 2 CAPTIVATE trial (NCT02910583) in chronic lymphocytic leukemia (CLL).

    Findings from the primary analysis of the fixed-duration cohort of the CAPTIVATE trial, which were presented during the 2021 ASCO Annual Meeting, demonstrated a complete response (CR) rate of 56% with the fixed-duration combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with CLL/small lymphocytic lymphoma without a 17p deletion. Moreover, a similar CR rate was observed in patients with high-risk features.

    Novel, oral medications given continuously revolutionized the treatment of patients with CLL and extended median progression-free and overall survival, Ghia says. However, fixed-duration treatment could spare patients the long-term adverse effects associated with continuous medication, Ghia says. Also, these regimens could prevent gene mutation recurrences, which lead to drug resistance, concludes Ghia.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data